Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the... see more

Recent & Breaking News (NDAQ:RIGL)

Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2019

Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City

PR Newswire December 5, 2018

New Research Coverage Highlights Weight Watchers International, Rudolph Technologies, Lowe's Companies, Net 1 UEPS Technologies, Viasat, and Rigel Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire December 3, 2018

Technological Advancements Show Growth in the Hospital Acquired Infection Control Market

PR Newswire November 16, 2018

Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update

PR Newswire November 6, 2018

Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition

PR Newswire November 1, 2018

Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results

PR Newswire October 30, 2018

Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries

PR Newswire October 29, 2018

Analysis: Positioning to Benefit within Spectrum Pharmaceuticals, Carnival, Cadence Design, Tandem Diabetes Care, Rigel Pharmaceuticals, and Regeneron Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire October 24, 2018

26 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  October 11, 2018

Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients

PR Newswire October 11, 2018

Rigel to Host Investor & Analyst Day in New York City on October 4, 2018

PR Newswire September 27, 2018

Rigel to Present at the Cantor Global Healthcare Conference

PR Newswire September 24, 2018

New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire August 31, 2018

Rigel to Present at the 20th Annual Global Investment Conference in New York City

PR Newswire August 29, 2018

Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update

PR Newswire August 8, 2018

Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results

PR Newswire August 1, 2018

Recent Analysis Shows Synopsys, Rigel Pharmaceuticals, Fate Therapeutics, Philip Morris International, Sally Beauty, and Kimberly-Clark Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire July 27, 2018

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

PR Newswire June 26, 2018

Rigel Announces Poster Presentations at FOCIS Annual Meeting

PR Newswire June 20, 2018